{
  "main_header": {
    "sid": 1003496,
    "name": "Vineet Laborator",
    "stock_name": "Vineet Laborator",
    "full_name": "Vineet Laboratories Ltd",
    "name_url": "stocks-analysis/vineet-laborator",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "42.49",
    "chg": -0.77,
    "chgp": "-1.78%",
    "dir": -1,
    "prev_price": "43.26",
    "mcapval": "39.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 543298,
    "symbol": "VINEETLAB",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE505Y01010",
    "curr_date": "Dec 17",
    "curr_time": "",
    "bse_nse_vol": "55.0 k",
    "exc_status": "Active",
    "traded_date": "Dec 17, 2025",
    "traded_date_str": "2025 12 17",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/vineet-laborator-1003496-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Vineet Laborator falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-vineet-laborator-fallingrising-3760542",
        "imagepath": "",
        "date": "2025-12-17 01:14:03",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Short-Term Gains Contrasted with Long-Term Declines</strong></p>\n<p>Vineet Laboratories has experienced a notable short-term rally, with the stock appreciating by 9.41% over the past week, significantly outperforming the Sensex’s marginal 0.02% gain during the same period. This recent momentum suggests renewed investor interest or positive technical signals driving buying activity in the near term.</p>\n<p>However, this short-term strength contrasts sharply with the stock’s longer-term returns. Year-to-date, Vineet Laboratories has declined by 30.62%, while the Sensex has advanced by 8.37%. Over the last one year, the stock has fallen 26.68%, compared to a 3.59% gain in the benchmark index. Extending the horizon further, the three-year performance shows a 23.23% loss for Vineet Laboratories a..."
      },
      {
        "title": "Vineet Laborator Sees Revision in Market Assessment Amid Challenging Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/vineet-laborator-downgraded-to-strong-sell-amid-weak-fundamentals-and-declining-promoter-confidence-3750035",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/VineetLaborator_mojoScore_3750035.png",
        "date": "2025-12-07 10:10:30",
        "description": "Vineet Laborator, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment reflecting ongoing challenges in its financial and operational metrics. The recent shift in evaluation metrics highlights concerns across quality, valuation, financial trends, and technical outlook, underscoring the complexities facing the company in a competitive industry environment."
      },
      {
        "title": "Why is Vineet Laborator falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-vineet-laborator-fallingrising-3713385",
        "imagepath": "",
        "date": "2025-11-18 23:36:37",
        "description": "As of 18-Nov, Vineet Laboratories Ltd is experiencing a decline in its stock price, currently at Rs 41.23, reflecting a decrease of Rs 1.07 or 2.53%. The stock has been underperforming, having fallen consecutively for the last four days, resulting in a total decline of 10.27% during this period. Additionally, the stock has shown a significant underperformance compared to the sector, with a daily performance lagging by 1.91%. Over the past year, the stock has generated negative returns of 16.11%, contrasting sharply with the Sensex, which has increased by 9.48%. The company's weak long-term fundamentals, highlighted by a staggering -230.87% CAGR growth in operating profits over the last five years and a high Debt to EBITDA ratio of 10.01 times, further contribute to the negative sentiment surrounding the stock. The promoters' reduced stake by 13.37% in the last quarter also signals a lack of confidence in th..."
      },
      {
        "title": "Why is Vineet Laborator falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-vineet-laborator-fallingrising-3702743",
        "imagepath": "",
        "date": "2025-11-14 23:31:34",
        "description": "As of 14-Nov, Vineet Laboratories Ltd is experiencing a decline in its stock price, currently at 43.43, which reflects a decrease of 0.39 or 0.89%. The stock has been underperforming, having fallen consecutively for the last two days with a total return of -5.48% during this period. Additionally, the stock's performance today has underperformed its sector by 1.26%. In terms of returns compared to benchmarks, the stock has shown a significant decline of 30.34% year-to-date and 22.45% over the past year, while the Sensex has increased by 8.22% and 9.00% respectively. The stock's delivery volume has also decreased by 7.37% against the 5-day average, indicating falling investor participation.\n\nBroader Market Context: In the short term, Vineet Laboratories Ltd has underperformed compared to the Sensex, which has gained 1.62% over the past week while the stock has dropped by 5.34%. This stark contrast highlights ..."
      },
      {
        "title": "How has been the historical performance of Vineet Laborator?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-vineet-laborator-3683733",
        "imagepath": "",
        "date": "2025-11-09 22:48:55",
        "description": "Answer:\nThe historical performance of Vineet Laborator shows a significant decline in key financial metrics over the past few years, culminating in a challenging fiscal year ending March 2025.\n\nBreakdown:\nVineet Laborator's net sales have decreased from 243.48 Cr in March 2021 to just 75.00 Cr in March 2025, reflecting a downward trend in revenue. The total operating income followed a similar pattern, dropping from 243.48 Cr in March 2021 to 75.00 Cr in March 2025. The company's total expenditure, excluding depreciation, also decreased from 235.33 Cr in March 2021 to 91.28 Cr in March 2025, yet the operating profit (PBDIT) turned negative, showing a loss of 16.28 Cr in March 2025 compared to a profit of 8.15 Cr in March 2021. This resulted in a profit before tax of -20.78 Cr in March 2025, down from 4.06 Cr in March 2021, and a profit after tax of -20.19 Cr, contrasting with a profit of 1.78 Cr in March 202..."
      },
      {
        "title": "Are Vineet Laborator latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-vineet-laborator-latest-results-good-or-bad-3683340",
        "imagepath": "",
        "date": "2025-11-09 19:16:08",
        "description": "The latest financial results for Vineet Laboratories present a mixed picture, highlighting both operational challenges and some positive developments. In the second quarter of FY26, the company reported a net profit of ₹0.40 crores, a notable turnaround from a loss of ₹0.87 crores in the previous quarter. This improvement in profitability is encouraging; however, it comes against a backdrop of declining revenues, with net sales of ₹17.42 crores reflecting an 8.12% decrease year-on-year.\n\nThe operating margin showed significant improvement, rising to 18.25% from 4.30% in the prior quarter, indicating enhanced operational efficiency. Additionally, the profit after tax (PAT) margin also improved to 2.30%, up from a negative margin in the previous quarter. These margin expansions suggest that cost management strategies may be yielding results, although they are primarily driven by cost compression rather than r..."
      },
      {
        "title": "Vineet Laboratories Q2 FY26: Profitability Returns But Revenue Concerns Persist",
        "link": "https://www.marketsmojo.com/news/result-analysis/vineet-laboratories-q2-fy26-profitability-returns-but-revenue-concerns-persist-3682544",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/VineetLaborator_quaterlyResult_3682544.png",
        "date": "2025-11-08 20:03:24",
        "description": "Vineet Laboratories Ltd., a micro-cap pharmaceutical intermediates manufacturer, posted a net profit of ₹0.40 crores in Q2 FY26, marking a dramatic turnaround from the ₹0.87 crores loss recorded in the previous quarter. However, the profitability recovery was overshadowed by persistent revenue challenges, with net sales declining 8.12% year-on-year to ₹17.42 crores, raising questions about the sustainability of this turnaround."
      },
      {
        "title": "How has been the historical performance of Vineet Laborator?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-vineet-laborator-3668225",
        "imagepath": "",
        "date": "2025-11-03 22:55:41",
        "description": "Answer:\nThe historical performance of Vineet Laborator has shown significant fluctuations over the years, particularly in its revenue and profitability metrics.\n\nBreakdown:\nVineet Laborator's net sales have declined from 243.48 Cr in Mar'21 to just 75.00 Cr in Mar'25, indicating a downward trend in revenue generation. The total operating income followed a similar pattern, decreasing from 243.48 Cr in Mar'21 to 75.00 Cr in Mar'25. The company's total expenditure, excluding depreciation, also decreased from 235.33 Cr in Mar'21 to 91.28 Cr in Mar'25, but not at a pace sufficient to maintain profitability, leading to an operating profit (PBDIT) that turned negative at -14.29 Cr in Mar'25 compared to a positive 8.54 Cr in Mar'21. Consequently, profit before tax fell sharply to -20.78 Cr in Mar'25 from 4.06 Cr in Mar'21, and profit after tax also turned negative at -20.19 Cr in Mar'25, down from 1.78 Cr in Mar'21..."
      },
      {
        "title": "Vineet Laboratories Faces Financial Struggles Amid Mixed Technical Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/vineet-laboratories-stock-rating-upgraded-from-strong-sell-to-sell-3654855",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/VineetLaborator_mojoScore_3654855.png",
        "date": "2025-10-29 08:42:50",
        "description": "Vineet Laboratories, a microcap in the Pharmaceuticals & Biotechnology sector, has experienced a recent evaluation adjustment due to shifts in technical indicators. Despite some bullish trends, the company faces significant financial challenges, including declining net sales and profit, low inventory turnover, and weak long-term fundamentals, raising concerns about its future."
      }
    ],
    "total": 270,
    "sid": "1003496",
    "stock_news_url": "https://www.marketsmojo.com/news/vineet-laboratories-1003496"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Meeting Updates",
      "datetime": "15-Dec-2025",
      "details": "In continuation to our communication dated December 12 2025 regarding the convening of meeting of Rights Issue Committee on December 15 2025 we inform you that the meeting which was commenced today at 7:00 PM is adjourned to Tuesday December 16 2025.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Meeting Updates",
      "datetime": "12-Dec-2025",
      "details": "In continuation to our communication dated December 11 2025 regarding the convening of the meeting of the Rights Issue Committee on December 12 2025 we inform you that the meeting which commenced today at 6.00 P.M. is adjourned to Monday December 15 2025.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Meeting Updates",
      "datetime": "11-Dec-2025",
      "details": "In continuation to our communication dated December 09 2025 regarding convening of the meeting of the Rights Issue Committee on December 11 2025 we inform you that the meeting commenced today at 6.00 PM is adjourned to Friday December 12 2025.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Vineet Laboratories Ltd has declared <strong>10%</strong> dividend, ex-date: 19 Sep 22",
          "dt": "2022-09-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Vineet Laborator falling/rising?

2025-12-17 01:14:03

Short-Term Gains Contrasted with Long-Term Declines

Vineet Laboratories has experienced a notable short-term rally, with the stock appreciating by 9.41% over the past week, significantly outperforming the Sensex’s marginal 0.02% gain during the same period. This recent momentum suggests renewed investor interest or positive technical signals driving buying activity in the near term.

However, this short-term strength contrasts sharply with the stock’s longer-term returns. Year-to-date, Vineet Laboratories has declined by 30.62%, while the Sensex has advanced by 8.37%. Over the last one year, the stock has fallen 26.68%, compared to a 3.59% gain in the benchmark index. Extending the horizon further, the three-year performance shows a 23.23% loss for Vineet Laboratories a...

Read More

Vineet Laborator Sees Revision in Market Assessment Amid Challenging Fundamentals

2025-12-07 10:10:30

Vineet Laborator, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment reflecting ongoing challenges in its financial and operational metrics. The recent shift in evaluation metrics highlights concerns across quality, valuation, financial trends, and technical outlook, underscoring the complexities facing the company in a competitive industry environment.

Read More

Why is Vineet Laborator falling/rising?

2025-11-18 23:36:37

As of 18-Nov, Vineet Laboratories Ltd is experiencing a decline in its stock price, currently at Rs 41.23, reflecting a decrease of Rs 1.07 or 2.53%. The stock has been underperforming, having fallen consecutively for the last four days, resulting in a total decline of 10.27% during this period. Additionally, the stock has shown a significant underperformance compared to the sector, with a daily performance lagging by 1.91%. Over the past year, the stock has generated negative returns of 16.11%, contrasting sharply with the Sensex, which has increased by 9.48%. The company's weak long-term fundamentals, highlighted by a staggering -230.87% CAGR growth in operating profits over the last five years and a high Debt to EBITDA ratio of 10.01 times, further contribute to the negative sentiment surrounding the stock. The promoters' reduced stake by 13.37% in the last quarter also signals a lack of confidence in th...

Read More

Why is Vineet Laborator falling/rising?

2025-11-14 23:31:34

As of 14-Nov, Vineet Laboratories Ltd is experiencing a decline in its stock price, currently at 43.43, which reflects a decrease of 0.39 or 0.89%. The stock has been underperforming, having fallen consecutively for the last two days with a total return of -5.48% during this period. Additionally, the stock's performance today has underperformed its sector by 1.26%. In terms of returns compared to benchmarks, the stock has shown a significant decline of 30.34% year-to-date and 22.45% over the past year, while the Sensex has increased by 8.22% and 9.00% respectively. The stock's delivery volume has also decreased by 7.37% against the 5-day average, indicating falling investor participation. Broader Market Context: In the short term, Vineet Laboratories Ltd has underperformed compared to the Sensex, which has gained 1.62% over the past week while the stock has dropped by 5.34%. This stark contrast highlights ...

Read More

How has been the historical performance of Vineet Laborator?

2025-11-09 22:48:55

Answer: The historical performance of Vineet Laborator shows a significant decline in key financial metrics over the past few years, culminating in a challenging fiscal year ending March 2025. Breakdown: Vineet Laborator's net sales have decreased from 243.48 Cr in March 2021 to just 75.00 Cr in March 2025, reflecting a downward trend in revenue. The total operating income followed a similar pattern, dropping from 243.48 Cr in March 2021 to 75.00 Cr in March 2025. The company's total expenditure, excluding depreciation, also decreased from 235.33 Cr in March 2021 to 91.28 Cr in March 2025, yet the operating profit (PBDIT) turned negative, showing a loss of 16.28 Cr in March 2025 compared to a profit of 8.15 Cr in March 2021. This resulted in a profit before tax of -20.78 Cr in March 2025, down from 4.06 Cr in March 2021, and a profit after tax of -20.19 Cr, contrasting with a profit of 1.78 Cr in March 202...

Read More

Are Vineet Laborator latest results good or bad?

2025-11-09 19:16:08

The latest financial results for Vineet Laboratories present a mixed picture, highlighting both operational challenges and some positive developments. In the second quarter of FY26, the company reported a net profit of ₹0.40 crores, a notable turnaround from a loss of ₹0.87 crores in the previous quarter. This improvement in profitability is encouraging; however, it comes against a backdrop of declining revenues, with net sales of ₹17.42 crores reflecting an 8.12% decrease year-on-year. The operating margin showed significant improvement, rising to 18.25% from 4.30% in the prior quarter, indicating enhanced operational efficiency. Additionally, the profit after tax (PAT) margin also improved to 2.30%, up from a negative margin in the previous quarter. These margin expansions suggest that cost management strategies may be yielding results, although they are primarily driven by cost compression rather than r...

Read More

Vineet Laboratories Q2 FY26: Profitability Returns But Revenue Concerns Persist

2025-11-08 20:03:24

Vineet Laboratories Ltd., a micro-cap pharmaceutical intermediates manufacturer, posted a net profit of ₹0.40 crores in Q2 FY26, marking a dramatic turnaround from the ₹0.87 crores loss recorded in the previous quarter. However, the profitability recovery was overshadowed by persistent revenue challenges, with net sales declining 8.12% year-on-year to ₹17.42 crores, raising questions about the sustainability of this turnaround.

Read More

How has been the historical performance of Vineet Laborator?

2025-11-03 22:55:41

Answer: The historical performance of Vineet Laborator has shown significant fluctuations over the years, particularly in its revenue and profitability metrics. Breakdown: Vineet Laborator's net sales have declined from 243.48 Cr in Mar'21 to just 75.00 Cr in Mar'25, indicating a downward trend in revenue generation. The total operating income followed a similar pattern, decreasing from 243.48 Cr in Mar'21 to 75.00 Cr in Mar'25. The company's total expenditure, excluding depreciation, also decreased from 235.33 Cr in Mar'21 to 91.28 Cr in Mar'25, but not at a pace sufficient to maintain profitability, leading to an operating profit (PBDIT) that turned negative at -14.29 Cr in Mar'25 compared to a positive 8.54 Cr in Mar'21. Consequently, profit before tax fell sharply to -20.78 Cr in Mar'25 from 4.06 Cr in Mar'21, and profit after tax also turned negative at -20.19 Cr in Mar'25, down from 1.78 Cr in Mar'21...

Read More

Vineet Laboratories Faces Financial Struggles Amid Mixed Technical Trends

2025-10-29 08:42:50

Vineet Laboratories, a microcap in the Pharmaceuticals & Biotechnology sector, has experienced a recent evaluation adjustment due to shifts in technical indicators. Despite some bullish trends, the company faces significant financial challenges, including declining net sales and profit, low inventory turnover, and weak long-term fundamentals, raising concerns about its future.

Read More

View All News